Ladenburg Thalmann Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2019
Q4 | $88K | Sell |
25,673
-500
| -2% | -$1.71K | ﹤0.01% | 3119 |
|
2019
Q3 | $75K | Buy |
26,173
+25,550
| +4,101% | +$73.2K | ﹤0.01% | 3142 |
|
2019
Q2 | $3K | Buy |
623
+134
| +27% | +$645 | ﹤0.01% | 4850 |
|
2019
Q1 | $4K | Buy |
489
+100
| +26% | +$818 | ﹤0.01% | 4720 |
|
2018
Q4 | $3K | Sell |
389
-100
| -20% | -$771 | ﹤0.01% | 4738 |
|
2018
Q3 | $4K | Buy |
489
+100
| +26% | +$818 | ﹤0.01% | 4658 |
|
2018
Q2 | $2K | Hold |
389
| – | – | ﹤0.01% | 4838 |
|
2018
Q1 | $2K | Hold |
389
| – | – | ﹤0.01% | 4838 |
|
2017
Q4 | $2K | Hold |
389
| – | – | ﹤0.01% | 4750 |
|
2017
Q3 | $2K | Hold |
389
| – | – | ﹤0.01% | 4644 |
|
2017
Q2 | $2K | Hold |
389
| – | – | ﹤0.01% | 4569 |
|
2017
Q1 | $3K | Hold |
389
| – | – | ﹤0.01% | 4452 |
|
2016
Q4 | $2K | Hold |
389
| – | – | ﹤0.01% | 4509 |
|
2016
Q3 | $2K | Sell |
389
-20,000
| -98% | -$103K | ﹤0.01% | 4448 |
|
2016
Q2 | $58K | Buy |
20,389
+10,000
| +96% | +$28.4K | ﹤0.01% | 2563 |
|
2016
Q1 | $29K | Buy |
10,389
+10,000
| +2,571% | +$27.9K | ﹤0.01% | 2983 |
|
2015
Q4 | $4K | Hold |
389
| – | – | ﹤0.01% | 4109 |
|
2015
Q3 | $4K | Sell |
389
-7,000
| -95% | -$72K | ﹤0.01% | 4013 |
|
2015
Q2 | $110K | Buy |
7,389
+3,500
| +90% | +$52.1K | ﹤0.01% | 2032 |
|
2015
Q1 | $35K | Buy |
3,889
+389
| +11% | +$3.5K | ﹤0.01% | 2814 |
|
2014
Q4 | $43K | Buy |
3,500
+500
| +17% | +$6.14K | ﹤0.01% | 2459 |
|
2014
Q3 | $29K | Hold |
3,000
| – | – | ﹤0.01% | 2367 |
|
2014
Q2 | $38K | Buy |
+3,000
| New | +$38K | ﹤0.01% | 2212 |
|
2014
Q1 | – | Sell |
-1,000
| Closed | -$8K | – | 3752 |
|
2013
Q4 | $8K | Hold |
1,000
| – | – | ﹤0.01% | 3038 |
|
2013
Q3 | $7K | Sell |
1,000
-27,000
| -96% | -$189K | ﹤0.01% | 3017 |
|
2013
Q2 | $43K | Buy |
+28,000
| New | +$43K | ﹤0.01% | 1823 |
|